Albert W. Gianchetti

Amministratore Delegato presso Xylocor Therapeutics, Inc.

59 anni

Health Technology

Consumer Services

Profilo

Albert W.
Gianchetti is currently the President, Chief Executive Officer & Director at Xylocor Therapeutics, Inc. He previously worked as the Chief Commercial Officer & Senior Vice President at Vanda Pharmaceuticals, Inc. from 2007 to 2008 and as the Vice President-Global Commercial Strategy at GSK Plc.
He holds an MBA degree from Drexel University and an undergraduate degree from the University of Delaware.

Posizioni attive di Albert W. Gianchetti

Società	Posizione	Inizio
Xylocor Therapeutics, Inc. Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.	Amministratore Delegato	-

Tutte le posizioni attive di Albert W. Gianchetti

Precedenti posizioni note di Albert W. Gianchetti

Società	Posizione	Fine
VANDA PHARMACEUTICALS INC.	Corporate Officer/Principal	01/12/2008
GSK PLC	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Albert W. Gianchetti

Formazione di Albert W. Gianchetti

University of Delaware	Undergraduate Degree
Drexel University	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Albert W. Gianchetti

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
VANDA PHARMACEUTICALS INC.	Health Technology
GSK PLC	Health Technology

Aziende private	1
Xylocor Therapeutics, Inc. Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.	Health Technology